HHP Medication Safety Watch: July 2025

Harvard Health Publishing shares selected recalls, withdrawals, and alerts from the FDA, drug and supplement makers, and other sources. We’ve provided links to information for each product. Unless otherwise noted, these actions apply only to the specific brand name of the product listed. Talk to your health care provider before stopping or changing any medicines or treatments that they have recommended for you.

• Prescription medicines

Prescription medicines

Stimulant medicines for ADHD may cause weight loss in young children

Comment: The FDA has issued a new warning about a risk for weight loss when extended-release stimulant medicines for attention deficit hyperactivity disorder (ADHD) are given to children who are younger than age 6.

The warning focuses on certain extended-release forms of amphetamine and methylphenidate. The makers of these drugs will be required to attach revised labels that include the new warning.

If a young child taking these medicines begins to lose weight, their parent or guardian is advised to review the risks and benefits of continuing this treatment with the health care provider who prescribed it. Together they should consider other options, such as adjusting the dose, switching to an immediate-release form of the medicine, and/or trying behavioral therapies.

Ulcer medicine recalled due to lack of quality control

• Sucralfate tablets, 1 gram (maker: Nostrum Laboratories)

Comment: The maker of this medicine has recalled all lots after the company filed for bankruptcy and ceased operations, including its quality control program for this drug. Without rigorous quality control measures, the drug’s maker cannot assure proper dosing, stability, or purity. Although no specific risks have been identified, anyone taking the medicine affected by this recall is advised to stop taking it and contact their doctor about a potential replacement.

Sucralfate is prescribed mainly to prevent and treat ulcers in the stomach and upper intestines.

Read additional issues of HHP Medication Safety Watch